Blog

The SELECT trial has provided significant insights into the cardiovascular benefits of semaglutide, a GLP-1 receptor agonist, for individuals who are obese or overweight and do not have diabetes. This study aimed to determine whether semaglutide could reduce the incidence of major adverse cardiovascular events (MACE) in this population. Here’s a concise overview of the […]

Wegogy and Ozempic are in short supply. This has prompted a rise in fake products that have the potential to kill.

How to boost your clinic income. Medical Weight Loss is a great way to improve clinic income and to also add a more medical emphasis to your aesthetic clinic.

Welcome, finally to Wegovy, the weight loss licensed version of Ozempic to the UK. The clinical trials have shown never before seen results with this medication.

There are so many acronyms in science and particularly the field of medicine. I just wanted to go over a couple with regards to weight loss medication.

So, what is the difference between a GLP1-agonist and a DPP-4 Inhibitor, and how do they compare with regards to weight loss?